Rupert Vessey's most recent trade in Bio-Techne Corp was a trade of 3,511 Stock Options (Right to Buy) done . Disclosure was reported to the exchange on Oct. 24, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Bio-Techne Corp | Rupert Vessey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Oct 2024 | 3,511 | 3,511 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne Corp | Rupert Vessey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Oct 2024 | 1,462 | 9,347 (0%) | 0% | 0 | Common Stock | |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP & President, Research | Sale of securities on an exchange or to another person at price $ 67.06 per share. | 03 May 2023 | 50,385 | 47,751 (0%) | 0% | 67.1 | 3,378,818 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP & President, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 44,541 | 118,263 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP & President, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 44,541 | 0 | - | - | Performance Shares | |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP & President, Research | Payment of exercise price or tax liability using portion of securities received from the company at price $ 65.71 per share. | 10 Mar 2023 | 25,565 | 98,136 (0%) | 0% | 65.7 | 1,679,876 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP & President, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 7,824 | 73,493 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP & President, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 7,824 | 15,651 | - | - | Market Share Units | |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP & President, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 7,423 | 7,425 | - | - | Market Share Units | |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP & President, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 7,423 | 68,796 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP & President, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 7,147 | 77,265 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP & President, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 7,147 | 21,442 | - | - | Market Share Units | |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP & President, Research | Other type of transaction at price $ 0.00 per share. | 10 Mar 2023 | 5,438 | 123,701 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP & President, Research | Payment of exercise price or tax liability using portion of securities received from the company at price $ 65.71 per share. | 10 Mar 2023 | 4,659 | 70,118 (0%) | 0% | 65.7 | 306,143 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP & President, Research | Payment of exercise price or tax liability using portion of securities received from the company at price $ 65.71 per share. | 10 Mar 2023 | 4,500 | 65,669 (0%) | 0% | 65.7 | 295,695 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP & President, Research | Payment of exercise price or tax liability using portion of securities received from the company at price $ 65.71 per share. | 10 Mar 2023 | 3,774 | 73,722 (0%) | 0% | 65.7 | 247,990 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP & President, Research | Other type of transaction at price $ 0.00 per share. | 10 Mar 2023 | 1,373 | 70,169 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP & President, Research | Other type of transaction at price $ 0.00 per share. | 10 Mar 2023 | 1,284 | 74,777 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP & President, Research | Other type of transaction at price $ 0.00 per share. | 10 Mar 2023 | 231 | 77,496 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2022 | 8,792 | 65,871 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2022 | 8,792 | 8,792 | - | - | Restricted Stock Units | |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 81.13 per share. | 02 Dec 2022 | 4,498 | 61,373 (0%) | 0% | 81.1 | 364,923 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Sale of securities on an exchange or to another person at price $ 78.88 per share. | 07 Nov 2022 | 45,910 | 57,079 (0%) | 0% | 78.9 | 3,621,381 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Nov 2022 | 21,288 | 0 | - | - | Option (right to buy) | |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 72.42 per share. | 07 Nov 2022 | 21,288 | 77,516 (0%) | 0% | 72.4 | 1,541,677 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Nov 2022 | 8,491 | 0 | - | - | Option (right to buy) | |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Nov 2022 | 8,491 | 0 | - | - | Option (right to buy) | |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Nov 2022 | 8,491 | 0 | - | - | Option (right to buy) | |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 38.41 per share. | 07 Nov 2022 | 8,491 | 102,989 (0%) | 0% | 38.4 | 326,139 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 47.81 per share. | 07 Nov 2022 | 8,491 | 94,498 (0%) | 0% | 47.8 | 405,955 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 44.70 per share. | 07 Nov 2022 | 8,491 | 86,007 (0%) | 0% | 44.7 | 379,548 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Nov 2022 | 5,843 | 0 | - | - | Option (right to buy) | |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 70.89 per share. | 07 Nov 2022 | 5,843 | 56,228 (0%) | 0% | 70.9 | 414,210 | Common Stock, $0.10 par value |
| Bio-Techne Corp | Rupert Vessey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Oct 2022 | 865 | 865 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne Corp | Rupert Vessey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Oct 2022 | 338 | 1,565 (0%) | 0% | 0 | Common Stock | |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Sale of securities on an exchange or to another person at price $ 69.23 per share. | 16 Mar 2022 | 43,228 | 50,385 (0%) | 0% | 69.2 | 2,992,674 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Sale of securities on an exchange or to another person at price $ 69.27 per share. | 16 Mar 2022 | 31,331 | 46,308 (0%) | 0% | 69.3 | 2,170,298 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2022 | 21,288 | 0 | - | - | Option (right to buy) | |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 66.35 per share. | 16 Mar 2022 | 21,288 | 67,596 (0%) | 0% | 66.4 | 1,412,459 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2022 | 12,233 | 0 | - | - | Option (right to buy) | |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 54.29 per share. | 16 Mar 2022 | 12,233 | 85,123 (0%) | 0% | 54.3 | 664,130 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2022 | 8,490 | 8,491 | - | - | Option (right to buy) | |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 38.41 per share. | 16 Mar 2022 | 8,490 | 93,613 (0%) | 0% | 38.4 | 326,101 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2022 | 5,294 | 0 | - | - | Option (right to buy) | |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 55.52 per share. | 16 Mar 2022 | 5,294 | 72,890 (0%) | 0% | 55.5 | 293,923 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2022 | 42,884 | 42,884 | - | - | Performance Shares | |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2022 | 28,589 | 28,589 | - | - | Market Share Units | |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2022 | 7,824 | 81,213 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2022 | 7,824 | 23,475 | - | - | Market Share Units | |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2022 | 7,423 | 14,848 | - | - | Market Share Units | |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2022 | 7,423 | 76,707 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 68.42 per share. | 10 Mar 2022 | 4,452 | 77,639 (0%) | 0% | 68.4 | 304,606 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 68.42 per share. | 10 Mar 2022 | 4,299 | 73,389 (0%) | 0% | 68.4 | 294,138 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Other type of transaction at price $ 0.00 per share. | 10 Mar 2022 | 981 | 77,688 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Other type of transaction at price $ 0.00 per share. | 10 Mar 2022 | 878 | 82,091 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2022 | 23,350 | 0 | - | - | Restricted Stock Units | |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2022 | 23,350 | 79,587 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 68.63 per share. | 01 Mar 2022 | 10,303 | 69,284 (0%) | 0% | 68.6 | 707,095 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Feb 2022 | 3,593 | 0 | - | - | Restricted Stock Units | |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Feb 2022 | 3,593 | 57,549 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 64.99 per share. | 04 Feb 2022 | 1,312 | 56,237 (0%) | 0% | 65.0 | 85,267 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2021 | 45,029 | 76,989 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2021 | 45,029 | 0 | - | - | Restricted Stock Units | |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 62.35 per share. | 31 Dec 2021 | 23,033 | 53,956 (0%) | 0% | 62.4 | 1,436,108 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Sale of securities on an exchange or to another person at price $ 61.99 per share. | 16 Dec 2021 | 13,100 | 31,960 (0%) | 0% | 62.0 | 812,069 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Sale of securities on an exchange or to another person at price $ 61.98 per share. | 16 Dec 2021 | 6,198 | 45,060 (0%) | 0% | 62.0 | 384,183 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2021 | 8,792 | 55,756 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2021 | 8,792 | 17,584 | - | - | Restricted Stock Units | |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 55.41 per share. | 02 Dec 2021 | 4,498 | 51,258 (0%) | 0% | 55.4 | 249,234 | Common Stock, $0.10 par value |
| Bio-Techne Corp | Rupert Vessey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Oct 2021 | 633 | 633 | - | - | Stock Option (right to buy) | |
| Bio-Techne Corp | Rupert Vessey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Oct 2021 | 194 | 1,227 (0%) | 0% | 0 | Common Stock | |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Sale of securities on an exchange or to another person at price $ 68.08 per share. | 30 Jul 2021 | 140,653 | 46,964 (0%) | 0% | 68.1 | 9,575,656 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jul 2021 | 29,489 | 0 | - | - | Option (right to buy) | |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 63.41 per share. | 30 Jul 2021 | 29,489 | 81,765 (0%) | 0% | 63.4 | 1,869,897 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jul 2021 | 24,134 | 0 | - | - | Option (right to buy) | |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 61.34 per share. | 30 Jul 2021 | 24,134 | 132,277 (0%) | 0% | 61.3 | 1,480,380 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jul 2021 | 22,483 | 0 | - | - | Option (right to buy) | |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 60.53 per share. | 30 Jul 2021 | 22,483 | 154,760 (0%) | 0% | 60.5 | 1,360,896 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Sale of securities on an exchange or to another person at price $ 68.01 per share. | 30 Jul 2021 | 17,740 | 36,650 (0%) | 0% | 68.0 | 1,206,497 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jul 2021 | 17,630 | 0 | - | - | Option (right to buy) | |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 56.44 per share. | 30 Jul 2021 | 17,630 | 108,143 (0%) | 0% | 56.4 | 995,037 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 55.52 per share. | 30 Jul 2021 | 15,879 | 170,639 (0%) | 0% | 55.5 | 881,602 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jul 2021 | 15,879 | 3,494 | - | - | Option (right to buy) | |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jul 2021 | 8,489 | 8,491 | - | - | Option (right to buy) | |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jul 2021 | 8,489 | 8,491 | - | - | Option (right to buy) | |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 47.81 per share. | 30 Jul 2021 | 8,489 | 187,617 (0%) | 0% | 47.8 | 405,859 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 44.70 per share. | 30 Jul 2021 | 8,489 | 179,128 (0%) | 0% | 44.7 | 379,458 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jul 2021 | 6,305 | 0 | - | - | Option (right to buy) | |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 63.41 per share. | 30 Jul 2021 | 6,305 | 48,798 (0%) | 0% | 63.4 | 399,800 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jul 2021 | 5,843 | 0 | - | - | Option (right to buy) | |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jul 2021 | 5,843 | 0 | - | - | Option (right to buy) | |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 61.01 per share. | 30 Jul 2021 | 5,843 | 87,608 (0%) | 0% | 61.0 | 356,481 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 58.78 per share. | 30 Jul 2021 | 5,843 | 42,493 (0%) | 0% | 58.8 | 343,452 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jul 2021 | 2,905 | 0 | - | - | Option (right to buy) | |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 54.20 per share. | 30 Jul 2021 | 2,905 | 90,513 (0%) | 0% | 54.2 | 157,451 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jul 2021 | 1,651 | 0 | - | - | Option (right to buy) | |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 60.53 per share. | 30 Jul 2021 | 1,651 | 50,449 (0%) | 0% | 60.5 | 99,935 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jul 2021 | 1,454 | 0 | - | - | Option (right to buy) | |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 54.20 per share. | 30 Jul 2021 | 1,454 | 51,903 (0%) | 0% | 54.2 | 78,807 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jul 2021 | 373 | 0 | - | - | Option (right to buy) | |
| Bristol-Myers Squibb Co. | Rupert Vessey | EVP, Research & Early Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 56.44 per share. | 30 Jul 2021 | 373 | 52,276 (0%) | 0% | 56.4 | 21,052 | Common Stock, $0.10 par value |